Darunavir Glenmark

What Is Darunavir Glenmark and What Is It Used For?

Darunavir Glenmark is a prescription antiretroviral medicine containing the active substance darunavir, used in combination with other HIV medicines to treat human immunodeficiency virus type 1 (HIV-1) infection in adults, adolescents, and children aged 3 years and older. It belongs to the class of medicines known as protease inhibitors (PIs).

Darunavir works by blocking HIV protease, an enzyme the virus needs to produce mature, infectious viral particles. By inhibiting this enzyme, darunavir prevents the virus from replicating and spreading to new cells. This mechanism of action makes it a cornerstone of modern antiretroviral therapy, particularly in patients who have developed resistance to other protease inhibitors.

As a second-generation protease inhibitor, darunavir was specifically designed to maintain activity against HIV strains that have developed resistance to first-generation protease inhibitors such as lopinavir, atazanavir, and fosamprenavir. Clinical trials – including the landmark ARTEMIS, ODIN, and TITAN studies – have demonstrated that darunavir-based regimens achieve high rates of viral suppression (HIV RNA below 50 copies/mL) in both treatment-naive and treatment-experienced patients.

Darunavir Glenmark is a generic formulation manufactured by Glenmark Pharmaceuticals. It has been approved by the European Medicines Agency (EMA) as a bioequivalent alternative to the originator product. Generic medicines undergo rigorous regulatory evaluation to ensure they deliver the same therapeutic effect as the branded version, differing only in price and non-active excipients.

The medicine is authorised for the treatment of HIV-1 infection in the following populations:

• Adults (18 years and older) – both treatment-naive and treatment-experienced
• Adolescents (12 to 17 years, weighing at least 40 kg)
• Children (3 to 11 years, weighing at least 15 kg) – when used with appropriate dosing

What Should You Know Before Taking Darunavir Glenmark?

Before starting Darunavir Glenmark, your doctor needs to assess your complete medical history, current medications, and any known allergies. Certain medical conditions and drug combinations are contraindicated with darunavir or require careful monitoring.

Contraindications

Darunavir Glenmark must not be taken in the following circumstances:

• Hypersensitivity: Known allergy to darunavir or any of the excipients in the formulation. Darunavir contains a sulfonamide moiety, so patients with a known severe sulfonamide allergy should use this medicine with caution
• Severe hepatic impairment: Patients with severe liver disease (Child-Pugh Class C) must not take darunavir, as the drug is extensively metabolised by the liver
• Co-administration with certain medicines: Several drugs are strictly contraindicated due to the risk of life-threatening interactions when combined with darunavir boosted with ritonavir or cobicistat (see Drug Interactions section below)

Contraindicated co-medications include rifampicin, St John’s wort (Hypericum perforatum), oral midazolam, triazolam, ergot derivatives (ergotamine, dihydroergotamine, ergonovine, methylergonovine), simvastatin, lovastatin, sildenafil when used for pulmonary arterial hypertension, lomitapide, and certain other potent CYP3A inducers or sensitive CYP3A substrates with narrow therapeutic windows.

Warnings and Precautions

Talk to your doctor before taking Darunavir Glenmark if any of the following apply to you:

• Liver disease: Patients with underlying hepatic impairment, including chronic hepatitis B or C co-infection, have an increased risk of hepatotoxicity. Liver function tests should be monitored before starting treatment and at regular intervals thereafter. Cases of drug-induced hepatitis, acute hepatic failure, and even fatal hepatic events have been reported with darunavir
• Haemophilia: Increased bleeding events, including spontaneous skin haematomas and haemarthrosis, have been reported in patients with haemophilia type A and B treated with protease inhibitors
• Diabetes mellitus: New-onset diabetes, hyperglycaemia, and exacerbation of pre-existing diabetes have been reported during treatment with protease inhibitors. Blood glucose monitoring is advisable
• Dyslipidaemia: Protease inhibitor therapy has been associated with elevations in cholesterol and triglycerides. Lipid levels should be monitored and managed according to established cardiovascular risk guidelines
• Immune reconstitution inflammatory syndrome (IRIS): When antiretroviral therapy is initiated, the recovering immune system may mount an inflammatory response against previously quiescent opportunistic infections (e.g., Mycobacterium avium complex, cytomegalovirus, Pneumocystis jirovecii). This may require additional treatment
• Osteonecrosis: Cases of osteonecrosis have been reported in patients with advanced HIV disease and/or long-term exposure to combination antiretroviral therapy. Patients should be advised to seek medical attention if they experience joint pain, stiffness, or difficulty moving
• Skin reactions: Severe skin reactions, including erythema multiforme, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported. Discontinue treatment immediately if signs of severe skin or hypersensitivity reaction develop

Pregnancy and Breastfeeding

If you are pregnant, planning to become pregnant, or breastfeeding, consult your doctor before taking Darunavir Glenmark. Key considerations include:

Pregnancy: Darunavir boosted with ritonavir may be used during pregnancy when clinically indicated. International guidelines from the WHO, the British HIV Association (BHIVA), and the US Department of Health and Human Services (DHHS) include darunavir/ritonavir as an option in certain clinical scenarios, particularly for women who were already on a darunavir-based regimen before conception. However, pregnancy-related pharmacokinetic changes – particularly in the second and third trimesters – can significantly reduce darunavir plasma levels, potentially compromising viral suppression. Therapeutic drug monitoring (TDM) may be required. Importantly, cobicistat-boosted darunavir is not recommended during pregnancy because cobicistat exposure is substantially reduced, leading to subtherapeutic darunavir levels.

Breastfeeding: Women living with HIV are generally advised not to breastfeed to prevent postnatal transmission of the virus. This recommendation applies in settings where safe alternatives to breast milk are available. Darunavir is excreted in breast milk, and its effects on the nursing infant have not been fully studied. In resource-limited settings where the benefits of breastfeeding may outweigh the risks, local guidelines should be followed, and antiretroviral treatment should be continued throughout the breastfeeding period.

How Does Darunavir Glenmark Interact with Other Drugs?

Darunavir is primarily metabolised by the liver enzyme CYP3A4 and is also an inhibitor of CYP3A4. When boosted with ritonavir or cobicistat (both potent CYP3A4 inhibitors), drug interactions are extensive and clinically significant. Always inform your doctor of all medicines you are taking, including over-the-counter products and herbal remedies.

The pharmacokinetic enhancers ritonavir and cobicistat amplify darunavir’s interactions with other drugs because they inhibit CYP3A4 and, in ritonavir’s case, also CYP2D6 and P-glycoprotein. This means that many drugs which are substrates, inducers, or inhibitors of these enzymes will have altered blood levels when co-administered with boosted darunavir.

Understanding drug interactions is critical for patient safety. Some interactions can lead to dangerously elevated levels of co-administered drugs (increasing toxicity risk), while others can reduce darunavir levels below the therapeutic threshold (risking virological failure and resistance development).

Major Interactions – Contraindicated

The following medicines must not be co-administered with Darunavir Glenmark due to potentially life-threatening or treatment-compromising interactions:

Interactions Requiring Dose Adjustment or Monitoring

Several common medicines may be co-administered with darunavir but require dose modifications, alternative agents, or enhanced clinical monitoring:

What Is the Correct Dosage of Darunavir Glenmark?

The dose of Darunavir Glenmark depends on whether the patient is treatment-naive or treatment-experienced, their age, body weight, and the results of resistance testing. It must always be taken with food and co-administered with a pharmacokinetic enhancer (ritonavir or cobicistat).

Taking darunavir with food is essential. Clinical studies have shown that food increases darunavir bioavailability by approximately 30%, regardless of the type of food consumed. Patients should be counselled to always take their darunavir dose during or immediately after a meal.

Adults (18 years and older)

Children and Adolescents

Elderly Patients

Limited data are available for patients aged 65 years and older. No specific dose adjustment is recommended based on age alone. However, elderly patients should be monitored more closely due to the increased frequency of hepatic impairment, decreased renal function, and polypharmacy-related drug interactions in this population. Careful assessment of comorbidities and concomitant medications is essential.

Missed Dose

Adherence to antiretroviral therapy is critical for maintaining viral suppression and preventing resistance. If you miss a dose of Darunavir Glenmark:

• Once-daily regimen: If less than 12 hours have passed since the scheduled dose, take the missed dose with food as soon as possible and then resume the normal dosing schedule. If more than 12 hours have elapsed, skip the missed dose and take the next dose at the usual time
• Twice-daily regimen: If less than 6 hours have passed, take the missed dose with food immediately. If more than 6 hours have elapsed, skip the missed dose and take the next scheduled dose
• Never take a double dose to make up for a missed one

Overdose

There is no specific antidote for darunavir overdose. In cases of accidental overdose, contact your healthcare provider or local poison control centre immediately. Treatment is supportive and symptomatic, focusing on monitoring of vital signs and clinical status. Since darunavir is highly bound to plasma proteins (approximately 95%), it is unlikely to be significantly removed by haemodialysis. Induced vomiting or gastric lavage may be considered if the ingestion was recent, as per standard toxicological practice.

What Are the Side Effects of Darunavir Glenmark?

Like all medicines, Darunavir Glenmark can cause side effects, although not everybody gets them. The most common side effects include diarrhoea, nausea, headache, and rash. Most side effects are mild to moderate and tend to improve over the first weeks of treatment. Serious side effects are rare but include hepatotoxicity and severe skin reactions.

The side effect profile of darunavir has been established through extensive clinical trials involving thousands of patients and post-marketing surveillance. Side effects are categorised below by frequency according to the Medical Dictionary for Regulatory Activities (MedDRA) convention. It is important to note that many side effects attributed to darunavir may be partially related to the pharmacokinetic enhancer (ritonavir or cobicistat) or other antiretroviral agents in the combination regimen.

Long-term use of protease inhibitors as a class has been associated with metabolic complications including dyslipidaemia, insulin resistance, and changes in body fat distribution (lipodystrophy). Cardiovascular risk should be assessed periodically, and lifestyle modifications (diet, exercise) along with pharmacological interventions (e.g., statins, where appropriate and safe) should be considered.

Immune reconstitution inflammatory syndrome (IRIS) may occur in the first weeks or months after initiating antiretroviral therapy, as the recovering immune system responds to previously latent infections. This is not a side effect of darunavir specifically but rather a consequence of effective immune recovery. Symptoms depend on the underlying infection and may include fever, lymphadenopathy, and organ-specific inflammation.

How Should You Store Darunavir Glenmark?

Store Darunavir Glenmark at room temperature (below 30°C / 86°F) in the original packaging to protect from moisture. Keep out of reach of children. Do not use after the expiry date printed on the packaging.

Proper storage of medicines is essential to maintain their effectiveness and safety. Darunavir Glenmark film-coated tablets should be stored according to the following guidelines:

• Temperature: Store below 30°C (86°F). Do not refrigerate or freeze
• Moisture protection: Keep in the original packaging (blister or bottle) to protect from moisture
• Light: No special precautions regarding light exposure are required for the film-coated tablets
• Accessibility: Keep this medicine out of the sight and reach of children
• Expiry: Do not use this medicine after the expiry date stated on the carton and blister/bottle. The expiry date refers to the last day of that month

Do not dispose of medicines via household waste or wastewater. Ask your pharmacist about how to properly dispose of medicines you no longer use. Proper disposal helps protect the environment and prevents accidental ingestion by others.

What Does Darunavir Glenmark Contain?

Each Darunavir Glenmark 400 mg film-coated tablet contains 400 mg of the active substance darunavir (as darunavir ethanolate), along with inactive ingredients (excipients) necessary for tablet formulation.

The active substance is darunavir, present as darunavir ethanolate. Each film-coated tablet contains 400 mg of darunavir.

The excipients (inactive ingredients) typically found in darunavir film-coated tablets include:

• Tablet core: Colloidal anhydrous silica, microcrystalline cellulose, crospovidone, magnesium stearate, and hypromellose
• Film coating: Polyvinyl alcohol, titanium dioxide (E171), macrogol (polyethylene glycol), talc, and iron oxide yellow or red (depending on tablet colour)

The exact excipient composition may vary slightly between generic manufacturers. Patients with known intolerances or allergies to specific excipients should review the patient information leaflet included with their specific product. If you have concerns about any ingredient, consult your pharmacist or prescribing physician.

Darunavir Glenmark 400 mg tablets are typically light orange to orange-coloured, oval-shaped film-coated tablets. The appearance may vary depending on the specific manufacturing batch and formulation details approved by the regulatory authority.

Frequently Asked Questions About Darunavir Glenmark